Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 19/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.56 |
| ▸ | TMPRSS11D | O60235 | 1/20 | 0.46 |
| ▸ | CTRL | P40313 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10316467 | 0.94 | OPRK1 (0.76) | OPRK1OPRM1 | |
| SCHEMBL24001141 | 0.91 | OPRK1 (0.75) | OPRK1OPRM1 | |
| SCHEMBL13290877 | 0.89 | OPRK1 (0.69) | OPRK1OPRM1 | |
| SCHEMBL21886575 | 0.88 | OPRK1 (0.51) | OPRK1TMPRSS11DCTRL | |
| SCHEMBL10316468 | 0.88 | OPRK1 (0.76) | OPRK1OPRM1 | |
| SCHEMBL25729957 | 0.87 | OPRK1 (0.85) | OPRK1OPRM1 | |
| SCHEMBL21286543 | 0.87 | OPRK1 (0.55) | OPRK1OPRM1 | |
| SCHEMBL21286478 | 0.86 | OPRK1 (0.79) | OPRK1OPRM1 | |
| SCHEMBL19835420 | 0.86 | OPRK1 (0.89) | OPRK1OPRM1 | |
| SCHEMBL22957113 | 0.86 | TMPRSS11D (0.52) | OPRK1TMPRSS11DCTRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | CARA THERAPEUTICS, INC. (US) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11684674-B2 | Oral formulations of kappa opioid receptor agonists | OPRK1, OPRL1, OGFR | OPRK1 1/4885OPRM1 5/4885TMPRSS11D 2519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.